Molecular mechanisms of pulmonary vascular remodeling in pulmonary arterial hypertension

International Journal of Molecular Sciences

Volumn 17, Issue 5, 2016, Pages

  Leopold, Jane A ^a   Maron, Bradley A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

DNA damage; Endothelial to mesenchymal transition; Metabolism; microRNA; Mitochondria; Pulmonary arterial hypertension

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN RECEPTOR; BRCA1 PROTEIN; CALCIUM; CARNITINE PALMITOYLTRANSFERASE I; CAVEOLIN 1; CYTOKINE; ENDOGLIN; FATTY ACID; FIBROBLAST GROWTH FACTOR 2; GLUCOSE TRANSPORTER; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; IRON; LACTATE DEHYDROGENASE; MICRORNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PYRUVATE DEHYDROGENASE; PYRUVATE KINASE; REACTIVE OXYGEN METABOLITE; SMAD1 PROTEIN; SMAD4 PROTEIN; SMAD8 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; ZINC; ZINC TRANSPORTER;

APOPTOSIS; AUTOSOMAL DOMINANT DISORDER; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ABERRATION; DNA DAMAGE; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE CLUSTER; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; GENE SILENCING; GENETIC VARIABILITY; HEART RIGHT VENTRICLE FUNCTION; HUMAN; HYPOXIA; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; METABOLIC FLUX ANALYSIS; MITOCHONDRION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR REMODELING; GENE EXPRESSION REGULATION; GENETICS; HEMODYNAMICS; PATHOLOGY;

APOPTOSIS; CELL PROLIFERATION; DNA DAMAGE; GENE EXPRESSION REGULATION; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MICRORNAS; PULMONARY ARTERY; SIGNAL TRANSDUCTION; VASCULAR REMODELING;

EID: 84969180413     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17050761     Document Type: Review

References (72)

1. Hoeper, M.M.; Bogaard, H.J.; Condliffe, R.; Frantz, R.; Khanna, D.; Kurzyna, M.; Langleben, D.; Manes, A.; Satoh, T.; Torres, F.; et al. Definitions and diagnosis of pulmonary hypertension. J. Am. Coll. Cardiol. 2013, 62, D42-D50. [CrossRef] [PubMed]
2. Ling, Y.; Johnson, M.K.; Kiely, D.G.; Condliffe, R.; Elliot, C.A.; Gibbs, J.S.; Howard, L.S.; Pepke-Zaba, J.; Sheares, K.K.; Corris, P.A.; et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: Results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am. J. Respir. Crit. Care Med. 2012, 186, 790-796. [CrossRef] [PubMed]
3. McGoon, M.D.; Benza, R.L.; Escribano-Subias, P.; Jiang, X.; Miller, D.P.; Peacock, A.J.; Pepke-Zaba, J.; Pulido, T.; Rich, S.; Rosenkranz, S.; et al. Pulmonary arterial hypertension: Epidemiology and registries. J. Am. Coll. Cardiol. 2013, 62, D51-D59. [CrossRef] [PubMed]
4. Tuder, R.M.; Archer, S.L.; Dorfmuller, P.; Erzurum, S.C.; Guignabert, C.; Michelakis, E.; Rabinovitch, M.; Schermuly, R.; Stenmark, K.R.; Morrell, N.W. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J. Am. Coll. Cardiol. 2013, 62, D4-D12. [CrossRef] [PubMed]
5. International, P.P.H.C.; Lane, K.B.; Machado, R.D.; Pauciulo, M.W.; Thomson, J.R.; Phillips, J.A., 3rd; Loyd, J.E.; Nichols,W.C.; Trembath, R.C. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat. Genet. 2000, 26, 81-84.
6. Deng, Z.; Haghighi, F.; Helleby, L.; Vanterpool, K.; Horn, E.M.; Barst, R.J.; Hodge, S.E.; Morse, J.H.; Knowles, J.A. Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. Am. J. Respir. Crit. Care Med. 2000, 161, 1055-109. [CrossRef] [PubMed]
7. Thomson, J.; Machado, R.; Pauciulo, M.; Morgan, N.; Yacoub, M.; Corris, P.; McNeil, K.; Loyd, J.; Nichols, W.; Trembath, R. Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein tuype II receptor. J. Heart Lung Transplant. 2001, 20, 149. [CrossRef]
8. Machado, R.D.; Southgate, L.; Eichstaedt, C.A.; Aldred, M.A.; Austin, E.D.; Best, D.H.; Chung, W.K.; Benjamin, N.; Elliott, C.G.; Eyries, M.; et al. Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Hum. Mutat. 2015, 36, 1113-1127. [CrossRef] [PubMed]
9. Austin, E.D.; Ma, L.; LeDuc, C.; Rosenzweig, E.B.; Borczuk, A.; Phillips, J.A., III; Palomero, T.; Sumazin, P.; Kim, H.R.; Talati, M.H.; et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ. Cardiovasc. Genet. 2012, 5, 336-343. [CrossRef] [PubMed]
10. Ma, L.; Roman-Campos, D.; Austin, E.D.; Eyries, M.; Sampson, K.S.; Soubrier, F.; Germain, M.; Tregouet, D.A.; Borczuk, A.; Rosenzweig, E.B.; et al. A novel channelopathy in pulmonary arterial hypertension. N. Engl. J. Med. 2013, 369, 351-361. [CrossRef] [PubMed]
11. Eyries, M.; Montani, D.; Girerd, B.; Perret, C.; Leroy, A.; Lonjou, C.; Chelghoum, N.; Coulet, F.; Bonnet, D.; Dorfmuller, P.; et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat. Genet. 2014, 46, 65-69. [CrossRef] [PubMed]
12. Germain, M.; Eyries, M.; Montani, D.; Poirier, O.; Girerd, B.; Dorfmuller, P.; Coulet, F.; Nadaud, S.; Maugenre, S.; Guignabert, C.; et al. Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nat. Genet. 2013, 45, 518-521. [CrossRef] [PubMed]
13. Wang, G.; Knight, L.; Ji, R.; Lawrence, P.; Kanaan, U.; Li, L.; Das, A.; Cui, B.; Zou, W.; Penny, D.J.; et al. Early onset severe pulmonary arterial hypertension with "two-hit" digenic mutations in both BMPR2 and KCNA5 genes. Int. J. Cardiol. 2014, 177, e167-e169. [CrossRef] [PubMed]
14. Lee, S.D.; Shroyer, K.R.; Markham, N.E.; Cool, C.D.; Voelkel, N.F.; Tuder, R.M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J. Clin. Investig. 1998, 101, 927-934. [CrossRef] [PubMed]
15. Tuder, R.M.; Lee, S.D.; Cool, C.C. Histopathology of pulmonary hypertension. Chest 1998, 114, 1S-6S. [CrossRef] [PubMed]
16. Yeager, M.E.; Halley, G.R.; Golpon, H.A.; Voelkel, N.F.; Tuder, R.M. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ. Res. 2001, 88, E2-E11. [CrossRef] [PubMed]
17. Aldred, M.A.; Comhair, S.A.; Varella-Garcia, M.; Asosingh, K.; Xu, W.; Noon, G.P.; Thistlethwaite, P.A.; Tuder, R.M.; Erzurum, S.C.; Geraci, M.W.; et al. Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2010, 182, 1153-1160. [CrossRef] [PubMed]
18. Meloche, J.; Pflieger, A.; Vaillancourt, M.; Paulin, R.; Potus, F.; Zervopoulos, S.; Graydon, C.; Courboulin, A.; Breuils-Bonnet, S.; Tremblay, E.; et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014, 129, 786-797. [CrossRef] [PubMed]
19. De Jesus Perez, V.A.; Yuan, K.; Lyuksyutova, M.A.; Dewey, F.; Orcholski, M.E.; Shuffle, E.M.; Mathur, M.; Yancy, L., Jr.; Rojas, V.; Li, C.G.; et al. Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2014, 189, 1260-1272. [CrossRef] [PubMed]
20. Federici, C.; Drake, K.M.; Rigelsky, C.M.; McNelly, L.N.; Meade, S.L.; Comhair, S.A.; Erzurum, S.C.; Aldred, M.A. Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 2015, 192, 219-228. [CrossRef] [PubMed]
21. Li, M.; Vattulainen, S.; Aho, J.; Orcholski, M.; Rojas, V.; Yuan, K.; Helenius, M.; Taimen, P.; Myllykangas, S.; de Jesus Perez, V.; et al. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol. 2014, 50, 1118-1128. [CrossRef] [PubMed]
22. Ambros, V. microRNAs: Tiny regulators with great potential. Cell 2001, 107, 823-826. [CrossRef]
23. Courboulin, A.; Paulin, R.; Giguere, N.J.; Saksouk, N.; Perreault, T.; Meloche, J.; Paquet, E.R.; Biardel, S.; Provencher, S.; Cote, J.; et al. Role for miR-204 in human pulmonary arterial hypertension. J. Exp. Med. 2011, 208, 535-548. [CrossRef] [PubMed]
24. Rhodes, C.J.; Wharton, J.; Boon, R.A.; Roexe, T.; Tsang, H.;Wojciak-Stothard, B.; Chakrabarti, A.; Howard, L.S.; Gibbs, J.S.; Lawrie, A.; et al. Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2013, 187, 294-302. [CrossRef] [PubMed]
25. Bockmeyer, C.L.; Maegel, L.; Janciauskiene, S.; Rische, J.; Lehmann, U.; Maus, U.A.; Nickel, N.; Haverich, A.; Hoeper, M.M.; Golpon, H.A.; et al. Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. J. Heart Lung Transplant. 2012, 31, 764-772. [CrossRef] [PubMed]
26. Zhou, G.; Chen, T.; Raj, J.U. MicroRNAs in pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol. 2015, 52, 139-151. [CrossRef] [PubMed]
27. Caruso, P.; MacLean, M.R.; Khanin, R.; McClure, J.; Soon, E.; Southgate, M.; MacDonald, R.A.; Greig, J.A.; Robertson, K.E.; Masson, R.; et al. Dynamic Changes in Lung MicroRNA Profiles During the Development of Pulmonary Hypertension due to Chronic Hypoxia and Monocrotaline. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 716-723. [CrossRef] [PubMed]
28. White, K.; Lu, Y.; Annis, S.; Hale, A.E.; Chau, B.N.; Dahlman, J.E.; Hemann, C.; Opotowsky, A.R.; Vargas, S.O.; Rosas, I.; et al. Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension. EMBO Mol. Med. 2015, 7, 695-713. [CrossRef] [PubMed]
29. Potus, F.; Ruffenach, G.; Dahou, A.; Thebault, C.; Breuils-Bonnet, S.; Tremblay, È.; Nadeau, V.; Paradis, R.; Graydon, C.; Wong, R.; et al. Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension. Circulation 2015, 132, 932-943. [CrossRef] [PubMed]
30. Stevens, H.C.; Deng, L.; Grant, J.S.; Pinel, K.; Thomas, M.; Morrell, N.W.; MacLean, M.R.; Baker, A.H.; Denby, L. Regulation and function of miR-214 in pulmonary arterial hypertension. Pulm. Circ. 2016, 6, 109-117. [CrossRef] [PubMed]
31. Brock, M.; Trenkmann, M.; Gay, R.E.; Michel, B.A.; Gay, S.; Fischler, M.; Ulrich, S.; Speich, R.; Huber, L.C. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ. Res. 2009, 104, 1184-1191. [CrossRef] [PubMed]
32. Pullamsetti, S.S.; Doebele, C.; Fischer, A.; Savai, R.; Kojonazarov, B.; Dahal, B.K.; Ghofrani, H.A.; Weissmann, N.; Grimminger, F.; Bonauer, A.; et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2012, 185, 409-419. [CrossRef] [PubMed]
33. Cordes, K.R.; Sheehy, N.T.; White, M.P.; Berry, E.C.; Morton, S.U.; Muth, A.N.; Lee, T.H.; Miano, J.M.; Ivey, K.N.; Srivastava, D. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009, 460, 705-710. [CrossRef] [PubMed]
34. Boettger, T.; Beetz, N.; Kostin, S.; Schneider, J.; Kruger, M.; Hein, L.; Braun, T. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the miR143/145 gene cluster. J. Clin. Investig. 2009, 119, 2634-2647. [CrossRef] [PubMed]
35. Courboulin, A.; Tremblay, V.L.; Barrier, M.; Meloche, J.; Jacob, M.H.; Chapolard, M.; Bisserier, M.; Paulin, R.; Lambert, C.; Provencher, S.; et al. Kruppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir. Res. 2011, 12, 128. [CrossRef] [PubMed]
36. Caruso, P.; Dempsie, Y.; Stevens, H.C.; McDonald, R.A.; Long, L.; Lu, R.; White, K.; Mair, K.M.; McClure, J.D.; Southwood, M.; et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ. Res. 2012, 111, 290-300. [CrossRef] [PubMed]
37. Lee, C.; Mitsialis, S.A.; Aslam, M.; Vitali, S.H.; Vergadi, E.; Konstantinou, G.; Sdrimas, K.; Fernandez-Gonzalez, A.; Kourembanas, S. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 2012, 126, 2601-2611. [CrossRef] [PubMed]
38. Parikh, V.N.; Jin, R.C.; Rabello, S.; Gulbahce, N.; White, K.; Hale, A.; Cottrill, K.A.; Shaik, R.S.; Waxman, A.B.; Zhang, Y.Y.; et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 2012, 125, 1520-1532. [CrossRef] [PubMed]
39. Bertero, T.; Cottrill, K.; Krauszman, A.; Lu, Y.; Annis, S.; Hale, A.; Bhat, B.; Waxman, A.B.; Chau, B.N.; Kuebler,W.M.; et al. The microRNA-130/301 family controls vasoconstriction in pulmonary hypertension. J. Biol. Chem. 2015, 290, 2069-2085. [CrossRef] [PubMed]
40. Bertero, T.; Lu, Y.; Annis, S.; Hale, A.; Bhat, B.; Saggar, R.; Saggar, R.; Wallace, W.D.; Ross, D.J.; Vargas, S.O.; et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J. Clin. Investig. 2014, 124, 3514-3528. [CrossRef] [PubMed]
41. Paulin, R.; Michelakis, E.D. The metabolic theory of pulmonary arterial hypertension. Circ. Res. 2014, 115, 148-164. [CrossRef] [PubMed]
42. Kennedy, E.P.; Lehninger, A.L. Oxidation of fatty acids and tricarboxylic acid cycle intermediates by isolated rat liver mitochondria. J. Biol. Chem. 1949, 179, 957-972. [PubMed]
43. Randle, P.J.; Garland, P.B.; Hales, C.N.; Newsholme, E.A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1, 785-789. [CrossRef]
44. Warburg, O.;Wind, F.; Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8, 519-530. [CrossRef] [PubMed]
45. Archer, S.L. Mitochondrial dynamics-Mitochondrial fission and fusion in human diseases. N. Engl. J. Med. 2013, 369, 2236-2251. [PubMed]
46. Yu, A.Y.; Shimoda, L.A.; Iyer, N.V.; Huso, D.L.; Sun, X.; McWilliams, R.; Beaty, T.; Sham, J.S.;Wiener, C.M.; Sylvester, J.T.; et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J. Clin. Investig. 1999, 103, 691-696. [CrossRef] [PubMed]
47. Piao, L.; Sidhu, V.K.; Fang, Y.H.; Ryan, J.J.; Parikh, K.S.; Hong, Z.; Toth, P.T.; Morrow, E.; Kutty, S.; Lopaschuk, G.D.; et al. FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J. Mol. Med. 2013, 3, 333-346. [CrossRef] [PubMed]
48. Xu, W.; Koeck, T.; Lara, A.R.; Neumann, D.; DiFilippo, F.P.; Koo, M.; Janocha, A.J.; Masri, F.A.; Arroliga, A.C.; Jennings, C.; et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc. Natl. Acad. Sci. USA 2007, 104, 1342-1347. [CrossRef] [PubMed]
49. Marsboom, G.; Toth, P.T.; Ryan, J.J.; Hong, Z.; Wu, X.; Fang, Y.H.; Thenappan, T.; Piao, L.; Zhang, H.J.; Pogoriler, J.; et al. Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ. Res. 2012, 110, 1484-1497. [CrossRef] [PubMed]
50. Archer, S.L.; Marsboom, G.; Kim, G.H.; Zhang, H.J.; Toth, P.T.; Svensson, E.C.; Dyck, J.R.; Gomberg-Maitland, M.; Thébaud, B.; Husain, A.N.; et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: A basis for excessive cell proliferation and a new therapeutic target. Circulation 2010, 121, 2661-2671. [CrossRef] [PubMed]
51. Guignabert, C.; Tu, L.; Izikki, M.; Dewachter, L.; Zadigue, P.; Humbert, M.; Adnot, S.; Fadel, E.; Eddahibi, S. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22α-targeted overexpression of the serotonin transporter. FASEB J. 2009, 23, 4135-4147. [CrossRef] [PubMed]
52. Bonnet, S.; Michelakis, E.D.; Porter, C.J.; Andrade-Navarro, M.A.; Thebaud, B.; Bonnet, S.; Haromy, A.; Harry, G.; Moudgil, R.; McMurtry, M.S.; et al. An abnormal mitochondrial-hypoxia inducible factor-1α-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: Similarities to human pulmonary arterial hypertension. Circulation 2006, 113, 2630-2641. [CrossRef] [PubMed]
53. McMurtry, M.S.; Bonnet, S.; Wu, X.; Dyck, J.R.; Haromy, A.; Hashimoto, K.; Michelakis, E.D. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ. Res. 2004, 95, 830-840. [CrossRef] [PubMed]
54. 2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H570-H578. [CrossRef] [PubMed]
55. Zhao, L.; Oliver, E.; Maratou, K.; Atanur, S.S.; Dubois, O.D.; Cotroneo, E.; Chen, C.N.; Wang, L.; Arce, C.; Chabosseau, P.L.; et al. The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia. Nature 2015, 524, 356-360. [CrossRef] [PubMed]
56. Cotroneo, E.; Ashek, A.; Wang, L.; Wharton, J.; Dubois, O.; Bozorgi, S.; Busbridge, M.; Alavian, K.N.; Wilkins, M.R.; Zhao, L. Iron homeostasis and pulmonary hypertension: Iron deficiency leads to pulmonary vascular remodeling in the rat. Circ. Res. 2015, 116, 1680-1690. [CrossRef] [PubMed]
57. Ruiter, G.; Manders, E.; Happe, C.M.; Schalij, I.; Groepenhoff, H.; Howard, L.S.; Wilkins, M.R.; Bogaard, H.J.; Westerhof, N.; van der Laarse,W.J.; et al. Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency. Pulm. Circ. 2015, 5, 466-472. [CrossRef] [PubMed]
58. Bonnet, S.; Rochefort, G.; Sutendra, G.; Archer, S.L.; Haromy, A.;Webster, L.; Hashimoto, K.; Bonnet, S.N.; Michelakis, E.D. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc. Natl. Acad. Sci. USA 2007, 104, 11418-11423. [CrossRef] [PubMed]
59. 2+ currents in rat aortic smooth muscle cells in primary culture. Circ. Res. 1996, 79, 14-19. [CrossRef] [PubMed]
60. 2+ Channels in Pulmonary Venous Smooth Muscle Cells. Circ. J. 2015, 79, 2058-2068. [CrossRef] [PubMed]
61. Fernandez, R.A.;Wan, J.; Song, S.; Smith, K.A.; Gu, Y.; Tauseef, M.; Tang, H.; Makino, A.; Mehta, D.; Yuan, J.X. Upregulated expression of STIM2, TRPC6, and Orai2 contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype. Am. J. Physiol. Cell Physiol. 2015, 308, C581-C593. [CrossRef] [PubMed]
62. 2+ store segregation. Cardiovasc. Res. 2014, 103, 313-323. [CrossRef] [PubMed]
63. Hadri, L.; Kratlian, R.G.; Benard, L.; Maron, B.A.; Dorfmuller, P.; Ladage, D.; Guignabert, C.; Ishikawa, K.; Aguero, J.; Ibanez, B.; et al. Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension. Circulation 2013, 128, 512-523. [CrossRef] [PubMed]
64. Aguero, J.; Ishikawa, K.; Hadri, L.; Santos-Gallego, C.; Fish, K.; Kohlbrenner, E.; Hammoudi, N.; Kho, C.; Lee, A.; Ibanez, B.; et al. Intratracheal gene delivery of SERCA2a amerliorates chronic post-capillary pulmonary hypertension: A large animal model. J. Am. Coll. Cardiol. 2016, 67, 2032-2046. [CrossRef] [PubMed]
65. Aguero, J.; Ishikawa, K.; Hadri, L.; Santos-Gallego, C.; Fish, K.; Hammoudi, N.; Chaanine, A.; Torquato, S.; Naim, C.; Ibanez, B.; et al. Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model. Am. J. Physiol. Heart Circ. Physiol. 2014, 307, H1204-H1215. [CrossRef] [PubMed]
66. Frid, M.G.; Kale, V.A.; Stenmark, K.R. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ. Res. 2002, 90, 1189-1196. [CrossRef] [PubMed]
67. Krenning, G.; Barauna, V.G.; Krieger, J.E.; Harmsen, M.C.; Moonen, J.R. Endothelial Plasticity: Shifting Phenotypes through Force Feedback. Stem Cells Int. 2016, 2016, 9762959. [CrossRef] [PubMed]
68. Ranchoux, B.; Antigny, F.; Rucker-Martin, C.; Hautefort, A.; Pechoux, C.; Bogaard, H.J.; Dorfmuller, P.; Remy, S.; Lecerf, F.; Plante, S.; et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation 2015, 131, 1006-1018. [CrossRef] [PubMed]
69. Good, R.B.; Gilbane, A.J.; Trinder, S.L.; Denton, C.P.; Coghlan, G.; Abraham, D.J.; Holmes, A.M. Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension. Am. J. Pathol. 2015, 185, 1850-1858. [CrossRef] [PubMed]
70. Qiao, L.; Nishimura, T.; Shi, L.; Sessions, D.; Thrasher, A.; Trudell, J.R.; Berry, G.J.; Pearl, R.G.; Kao, P.N. Endothelial fate mapping in mice with pulmonary hypertension. Circulation 2014, 129, 692-703. [CrossRef] [PubMed]
71. Sheikh, A.Q.; Lighthouse, J.K.; Greif, D.M. Recapitulation of developing artery muscularization in pulmonary hypertension. Cell Rep. 2014, 6, 809-817. [CrossRef] [PubMed]
72. Sheikh, A.Q.; Misra, A.; Rosas, I.O.; Adams, R.H.; Greif, D.M. Smooth muscle cell progenitors are primed to muscularize in pulmonary hypertension. Sci. Transl. Med. 2015, 7, 308ra159. [CrossRef] [PubMed]